Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
You must be a Standard 1 Year member to access this content.
Goodwin advised Generate:Biomedicines on the fundraising. Generate:Biomedicines announced that it has raised $273 million in Series C financing. This financing round attracted many new investors including...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BioDelivery Sciences International on the deal while Troutman Pepper advised Collegium Pharmaceutical. BioDelivery Sciences International (NASDAQ: BDSI) announced its definitive merger agreement to be...
You must be a Standard 1 Year member to access this content.
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised G Squared Ascend I on the deal. Latham & Watkins represented Transfix. G Squared Ascend I (NYSE: GSQD), a special purpose acquisition company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Laronde on the deal. Laronde announced its $440 million Series B Financing to advance the development of its eRNA platform and a broad pipeline...
You must be a Standard 1 Year member to access this content.
